Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays.Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests that analyze static "genomic scars"—which may persist even after a patient develops drug resistance—this RNA-based approach provides a dynamic, real-time assessment of a tumor’s functional status.By analyzing gene expression rather than structural DNA damage, the algorithm can detect HRD in patients and cancer types where genomic scarring is rare or difficult to identi
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI (TEM) had its price target lowered by Morgan Stanley from $85.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
- Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision MedicineBusiness Wire
- Tempus AI (TEM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TEM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sellMarketBeat
- Tempus to Participate in the Morgan Stanley Technology, Media & Telecom ConferenceBusiness Wire
- Tempus AI: No AI Interruption Detected [Seeking Alpha]Seeking Alpha
TEM
Earnings
- 2/24/26 - Beat
TEM
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- TEM's page on the SEC website